MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.

Key Points Interested in Amgen Inc.? Here are five stocks we like better. Amgen said its strong first-quarter results support ...

The biotech giant is bucking the market trend, but its real value for investors lies in a story that unfolds over years, not ...

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and ...

View Amgen Inc. AMGN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 9:20 AM EDTCompany ParticipantsPeter Griffith - Executive ...

With the help of GLP-1 treatments, patients living with obesity and obesity-related conditions can define success on their ...

Shares of Amgen Inc. AMGN shed 1.98% to $337.73 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.62% to 7,266.99 and Dow ...

In the persistence and adherence analysis, which looked at 28 studies including 267,542 patients, Amgen found that 69% of ...

April 27 (Reuters) - The U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER) has proposed withdrawing approval of Amgen's drug for rare autoimmune diseases, citing a ...

The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries risk of liver injury.

Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new patients.